Publication
Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (19)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 19
- cancerLung Non-Small Cell Carcinomacivic_curation1.00
- drugTrastuzumab Deruxtecancivic_curation1.00
- geneERBB2civic_curation1.00
- variantERBB2 A775_G776insTVMAcivic_curation1.00
- variantERBB2 A775_G776insVcivic_curation1.00
- variantERBB2 A775_G776insVVMAcivic_curation1.00
- variantERBB2 Exon 20 Insertioncivic_curation1.00
- variantERBB2 G776delinsCVcivic_curation1.00
- variantERBB2 G776delinsLCcivic_curation1.00
- variantERBB2 G776delinsVCcivic_curation1.00
- variantERBB2 G776_V777delinsVCDcivic_curation1.00
- variantERBB2 G778_P780dupcivic_curation1.00
- variantERBB2 G778_S779insLPScivic_curation1.00
- variantERBB2 L755Acivic_curation1.00
- variantERBB2 L755Mcivic_curation1.00
- variantERBB2 L755Pcivic_curation1.00
- variantERBB2 Mutationcivic_curation1.00
- variantERBB2 S310Fcivic_curation1.00
- variantERBB2 Y772_A775DUPcivic_curation1.00
Curated evidence
Evidence citing this paper (19)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 37694347
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ERBB2 A775_G776insTVMA1 | ||||||||
| Trastuzumab Deruxtecan | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 2 | accepted | EID11755In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC) PMID 37694347 · Goto et al., 2023 · Open in CIViC | civic |
| ERBB2 A775_G776insV1 | ||||||||
| Trastuzumab Deruxtecan | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 2 | accepted | EID11756In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC) PMID 37694347 · Goto et al., 2023 · Open in CIViC | civic |
| ERBB2 A775_G776insVVMA1 | ||||||||
| Trastuzumab Deruxtecan | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 2 | accepted | EID11757In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC) PMID 37694347 · Goto et al., 2023 · Open in CIViC | civic |
| ERBB2 Exon 20 Insertion1 | ||||||||
| Trastuzumab Deruxtecan | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID11765In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC) PMID 37694347 · Goto et al., 2023 · Open in CIViC | civic |
| ERBB2 G776delinsCV1 | ||||||||
| Trastuzumab Deruxtecan | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID11759In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC) PMID 37694347 · Goto et al., 2023 · Open in CIViC | civic |
| ERBB2 G776delinsLC1 | ||||||||
| Trastuzumab Deruxtecan | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 2 | accepted | EID11760In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC) PMID 37694347 · Goto et al., 2023 · Open in CIViC | civic |
| ERBB2 G776delinsVC1 | ||||||||
| Trastuzumab Deruxtecan | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID11761In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC) PMID 37694347 · Goto et al., 2023 · Open in CIViC | civic |
| ERBB2 G776_V777delinsVCD1 | ||||||||
| Trastuzumab Deruxtecan | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 2 | accepted | EID11758In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC) PMID 37694347 · Goto et al., 2023 · Open in CIViC | civic |
| ERBB2 G778_P780dup1 | ||||||||
| Trastuzumab Deruxtecan | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 3 | accepted | EID11762In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC) PMID 37694347 · Goto et al., 2023 · Open in CIViC | civic |
| ERBB2 G778_S779insLPS1 | ||||||||
| Trastuzumab Deruxtecan | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 2 | accepted | EID11763In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC) PMID 37694347 · Goto et al., 2023 · Open in CIViC | civic |
| ERBB2 L755A1 | ||||||||
| Trastuzumab Deruxtecan | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 3 | accepted | EID11752In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC) PMID 37694347 · Goto et al., 2023 · Open in CIViC | civic |
| ERBB2 L755M1 | ||||||||
| Trastuzumab Deruxtecan | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 2 | accepted | EID11753In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC) PMID 37694347 · Goto et al., 2023 · Open in CIViC | civic |
| ERBB2 L755P1 | ||||||||
| Trastuzumab Deruxtecan | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 2 | accepted | EID11754In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC) PMID 37694347 · Goto et al., 2023 · Open in CIViC | civic |
| ERBB2 L755S1 | ||||||||
| Trastuzumab Deruxtecan | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12233In the phase 2 DESTINY-Lung02 trial, 152 metastatic NSCLC patients harbouring mutations in ERBB2 (HER2) were treated with the HER2 antibody-drug-conjugate (ADC) trastuzumab deruxtecan (5.4 mg/kg or 6.… (full text at CIViC) PMID 37694347 · Goto et al., 2023 · Open in CIViC | civic |
| ERBB2 L755W1 | ||||||||
| Trastuzumab Deruxtecan | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12234In the phase 2 DESTINY-Lung02 trial, 152 metastatic NSCLC patients harbouring mutations in ERBB2 (HER2) were treated with the HER2 antibody-drug-conjugate (ADC) trastuzumab deruxtecan (5.4 mg/kg or 6.… (full text at CIViC) PMID 37694347 · Goto et al., 2023 · Open in CIViC | civic |
| ERBB2 Mutation1 | ||||||||
| Trastuzumab Deruxtecan | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID11731In a phase 2 trial, 152 previously-treated metastatic NSCLC patients harboring mutations in ERBB2 (HER2) were treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 m… (full text at CIViC) PMID 37694347 · Goto et al., 2023 · Open in CIViC | civic |
| ERBB2 S310F1 | ||||||||
| Trastuzumab Deruxtecan | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 3 | accepted | EID11751In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC) PMID 37694347 · Goto et al., 2023 · Open in CIViC | civic |
| ERBB2 S310Y1 | ||||||||
| Trastuzumab Deruxtecan | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12232In the phase 2 DESTINY-Lung02 trial, 152 metastatic NSCLC patients harbouring mutations in ERBB2 (HER2) were treated with the HER2 antibody-drug-conjugate (ADC) trastuzumab deruxtecan (5.4 mg/kg or 6.… (full text at CIViC) PMID 37694347 · Goto et al., 2023 · Open in CIViC | civic |
| ERBB2 Y772_A775DUP1 | ||||||||
| Trastuzumab Deruxtecan | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID11764In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC) PMID 37694347 · Goto et al., 2023 · Open in CIViC | civic |